Health care company Astellas Pharma Inc (TSE:4503) revealed on Monday the availability of the XOSPATA for prescription in the US for the treatment of adult patients with Acute Myeloid Leukemia (AML), a cancer that impacts the blood and bone marrow and its incidence increases with age.
The company has introduced XOSPATA (generic name: gilteritinib) for prescription in the US for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation as detected by an US FDA-approved test.
According to the company, XOSPATA, which is an oral monotherapy, is the first and only FLT3-targeting agent approved by the US FDA for the treatment of relapsed or refractory FLT3 mutation-positive (FLT3mut+) AML.
In Japan, XOSPATA is launched as XOSPATA in 40 mg Tablets for relapsed or refractory AML with FLT3 mutations upon approval by the Japan Ministry of Health, Labor and Welfare (MHLW).
Additionally, the health professionals, patients and their caregivers can get support services for XOSPATA through Astellas at https://www.xospata.com/.
Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical Co Ltd, under which, Astellas is currently investigating gilteritinib in various FLT3 mutation-positive AML patient populations through several Phase 3 trials.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study